drugset / Trial / NCT05198362

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

NCT05198362

Phase 2 Withdrawn Saniona
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects with PWS.

Timeline

Start
2021-12-28
Primary completion
2022-12-09
Completion
2022-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Metoprolol Other / unclassified Oral
Subject Tesofensine Small molecule Oral

Indications